A review of the safety and efficacy of nebivolol in the mildly hypertensive patient

John Cockcroft*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

29 Citations (Scopus)


Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-blockers by its hemodynamic profile. It combines beta-adrenergic blocking activity with a vasodilating effect mediated by the endothelial L-arginine nitric oxide (NO) pathway. The effects of nebivolol have been compared with other beta-blockers and also with other classes of antihypertensive agents. In general, response rates to treatment are higher, and the frequency and severity of adverse events are either comparable or lower with nebivolol. Nebivolol is also effective in reducing cardiovascular morbidity and mortality in elderly patients with heart failure, regardless of the initial ejection fraction. Endothelium-derived NO is important in the regulation of large arterial stiffness, which in turn is a major risk factor for cardiovascular disease. Treatment with nebivolol increases the release of NO from the endothelium and improves endothelial function, leading to a reduction in arterial stiffness. Decreased arterial stiffness has beneficial hemodynamic effects including reductions in central aortic blood pressure. Unlike first generation beta-blockerrs, vasodilator beta-blockerrs such as nebivolol have favorable hemodynamic effect which may translate into improved cardiovascular outcomes in patients with hypertension.

Original languageEnglish
Pages (from-to)909-917
Number of pages9
JournalVascular Health and Risk Management
Issue number6
Publication statusPublished - 2007


  • Arterial stiffness
  • Beta-blocker
  • Heart failure
  • Hypertension
  • Nebivolol
  • Nitric oxide


Dive into the research topics of 'A review of the safety and efficacy of nebivolol in the mildly hypertensive patient'. Together they form a unique fingerprint.

Cite this